Alendronate/cRGD-Decorated Ultrafine Hyaluronate Dot Targeting Bone Metastasis
- Authors
- Lee, Eunsol; Park, Jaeduk; Youn, Yu Seok; Oh, Kyung Taek; Kim, Dongin; Lee, Eun Seong
- Issue Date
- Nov-2020
- Publisher
- MDPI
- Keywords
- hyaluronate dot; alendronate; cyclic RGD; bone metastasis; photodynamic tumor therpy
- Citation
- BIOMEDICINES, v.8, no.11, pp 1 - 17
- Pages
- 17
- Journal Title
- BIOMEDICINES
- Volume
- 8
- Number
- 11
- Start Page
- 1
- End Page
- 17
- URI
- https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/53950
- DOI
- 10.3390/biomedicines8110492
- ISSN
- 2227-9059
2227-9059
- Abstract
- In this study, we report the hyaluronate dot (dHA) with multiligand targeting ability and a photosensitizing antitumor model drug for treating metastatic bone tumors. Here, the dHA was chemically conjugated with alendronate (ALN, as a specific ligand to bone), cyclic arginine-glycine-aspartic acid (cRGD, as a specific ligand to tumor integrin alpha(v)beta(3)), and photosensitizing chlorin e6 (Ce6, for photodynamic tumor therapy), denoted as (ALN/cRGD)@dHA-Ce6. These dots thus prepared (approximate to 10 nm in diameter) enabled extensive cellular interactions such as hyaluronate (HA)-mediated CD44 receptor binding, ALN-mediated bone targeting, and cRGD-mediated tumor integrin alpha(v)beta(3) binding, thus improving their tumor targeting efficiency, especially for metastasized MDA-MB-231 tumors. As a result, these dots improved the tumor targeting efficiency and tumor cell permeability in a metastatic in vivo tumor model. Indeed, we demonstrated that (ALN/cRGD)@dHA-Ce6 considerably increased photodynamic tumor ablation, the extent of which is superior to that of the tumor ablation of dot systems with single or double ligands. These results indicate that dHA with multiligand can provide an effective treatment strategy for metastatic bone tumors.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Pharmacy > School of Pharmacy > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.